This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Cerebral infarction뇌경색증

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: I63 (cerebral infarction) | Special Copayment Reduction: V191 (Special Copayment Reduction for cerebrovascular disease: 5% copayment for up to 30 days from the registration date)
B. SynonymsIschemic stroke, cerebral ischemia, cerebral embolism, cerebral thrombosis
C. Adult onsetIncidence rises sharply after age 55, with the risk roughly doubling every 10 years. Atherosclerosis, atrial fibrillation, hypertension and diabetes are the main risk factors.
1. HistoryMajor milestones are Déjerine's classification of ischemic stroke in 1888, FDA approval of tPA thrombolysis in 1996, and the success of large clinical trials of endovascular mechanical thrombectomy in 2015.
2. CausesThe main causes are large artery atherosclerosis, cardioembolism (atrial fibrillation), small vessel disease (lacunar infarction) and other causes (coagulation disorders, arterial dissection).
3. GeneticsBesides monogenic diseases such as CADASIL (NOTCH3), Fabry disease (GLA), sickle cell anemia and factor V Leiden, dozens of susceptibility loci have been identified by GWAS.
4. General epidemiologyIt is the second most common cause of death worldwide and a major cause of disability, with about 13.4 million cases occurring worldwide each year.
5. PathophysiologyAfter vessel occlusion, an ischemic core and penumbra form, and secondary injury from excitotoxicity, oxidative stress and neuroinflammation progresses.
6. SymptomsThe main symptoms are sudden hemiplegia, speech disturbance, unilateral facial droop, visual disturbance, dizziness and gait disturbance (FAST criteria).
7. SignsUpper motor neuron signs (Babinski reflex, spastic paralysis), gaze deviation, hemianopia, aphasia and hemisensory loss appear according to the vascular territory.
8. ScreeningEarly detection and treatment of hypertension, diabetes, hyperlipidemia and atrial fibrillation are key, and carotid ultrasound and cerebrovascular imaging are considered in high-risk groups.
9. DiagnosisAfter excluding hemorrhage with non-contrast head CT, acute infarction is confirmed with DWI MRI, and the site of vessel occlusion is assessed with CTA/MRA.
10. TreatmentStandard treatment is intravenous thrombolysis (alteplase) within 4.5 hours of onset, endovascular mechanical thrombectomy within 24 hours, and subsequent secondary prevention with antiplatelet agents, anticoagulants and the like.
11. PrognosisThe 30-day mortality is about 10–15%, and the faster the reperfusion, the better the prognosis. About 40–50% of survivors have long-term disability.
12. PreventionControl of hypertension, diabetes and hyperlipidemia, smoking cessation, antiplatelet and anticoagulant therapy, and carotid endarterectomy are the keys to primary and secondary prevention.
13. ReferencesPowers WJ, et al. 2019 Guidelines for the Early Management of Patients With Acute Ischemic Stroke. Stroke. 2019 … and 9 other papers

1. History

Cerebral infarction is one of the oldest diseases in human history, and records of sudden paralysis and loss of consciousness remain even in ancient Egyptian and Greek texts. Hippocrates (around 400 BC) named this condition 'apoplexia', but its mechanism was not understood. In the 17th century, Johann Jakob Wepfer first described through autopsy that stroke results not only from cerebral hemorrhage but also from vessel occlusion. In the mid-19th century, Jean-Martin Charcot and Rudolf Virchow established the concept of cerebral thrombosis and described the link between atherosclerotic plaque formation and thrombus generation.

In 1888 the French neurologist Joseph Jules Déjerine laid the foundation for the first systematic classification of ischemic stroke into large-vessel thrombosis, embolism and small vessel disease. In the first half of the 20th century, hypertension and atherosclerosis were established as the main causes of stroke, and in 1958 C. Miller Fisher systematically described transient ischemic attack (TIA) and lacunar infarcts, contributing to the stroke classification system. Clinical application of CT in the 1970s made it possible to distinguish ischemic from hemorrhagic stroke during life, bringing about a fundamental change in treatment.

The most groundbreaking turning point in the treatment of cerebral infarction was the US FDA's approval of intravenous alteplase (tPA) thrombolysis in 1996. The NINDS tPA Stroke Study (1995) demonstrated in a randomized controlled trial that tPA given within 3 hours of onset significantly increases the likelihood of functional independence at 3 months. In 2008 the ECASS-III study provided evidence for extending the treatment window to 4.5 hours. In 2015, five large randomized controlled trials (MR CLEAN, ESCAPE, EXTEND-IA, SWIFT PRIME, THRACE) were published simultaneously, proving the superiority of mechanical thrombectomy for large vessel occlusion within 6 hours of onset, and the subsequently published DAWN and DEFUSE-3 studies provided evidence for extending the treatment window to 24 hours, revolutionizing the treatment paradigm for cerebral infarction.


2. Causes

Under the TOAST (Trial of Org 10172 in Acute Stroke Treatment) classification system, the causes of cerebral infarction are broadly classified into five categories. Large artery atherosclerosis accounts for about 25–30% of all ischemic strokes; the mechanism is atherosclerotic plaque formation in major cerebral vessels such as the internal carotid, middle cerebral, vertebral and basilar arteries, with thrombus formation or distal embolism. Hypertension, diabetes, hyperlipidemia and smoking are the main risk factors.

Cardioembolism accounts for about 20–30% of the total, and nonvalvular atrial fibrillation is the most important cause. In atrial fibrillation, thrombus forms in the left atrial appendage and sends emboli to the brain. Other cardiac sources include ventricular thrombus after myocardial infarction, valvular heart disease (mitral stenosis, prosthetic valves), endocarditis, atrial septal defect and patent foramen ovale (PFO), dilated cardiomyopathy and atrial myxoma. Small vessel disease (lacunar infarction) accounts for about 20–25% of the total and is characterized by lacunar infarcts in the deep brain (basal ganglia, thalamus, internal capsule, pons); the main mechanism is lipohyalinosis of small penetrating arteries due to chronic hypertension and diabetes.

Other determined causes include arterial dissection (carotid/vertebral artery dissection, especially important in young patients), inherited thrombophilia (factor V Leiden variant, prothrombin gene variant, protein C/S deficiency), antiphospholipid syndrome, vasculitis (Takayasu arteritis, primary CNS vasculitis), moyamoya disease, Fabry disease, mitochondrial disease (MELAS) and sickle cell anemia. Cryptogenic stroke, in which the cause cannot be identified despite complete evaluation, accounts for about 25–30%, and occult atrial fibrillation is now recognized as a likely possibility.


3. Genetics

Cerebral infarction is a complex multifactorial disease in which genetic predisposition is important. Cerebral infarction due to monogenic disease is rare but clinically important. CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) is an autosomal dominant cerebrovascular disease caused by NOTCH3 gene variants, characterized by recurrent ischemic attacks due to small vessel disease and progressive cognitive decline. In Fabry disease (Anderson-Fabry disease), X-linked GLA gene variants cause alpha-galactosidase A deficiency, leading to glycolipid accumulation in vascular endothelial cells and cerebral infarction.

Thrombosis-related gene variants are also important. The factor V Leiden (FVL) variant (F5 gene c.1691G>A) is a common thrombotic risk variant in Europeans and is associated with cerebral venous sinus thrombosis and ischemic stroke in young patients. The prothrombin G20210A variant (F2 gene) confers a similar thrombotic tendency. The MTHFR C677T variant causes hyperhomocysteinemia, promoting vascular damage and thrombus formation, and is associated with the risk of cerebral infarction. Genome-wide association studies (GWAS) have identified dozens of susceptibility loci, including PITX2 (atrial fibrillation–related stroke), ZFHX3, HDAC9 (large artery atherosclerotic stroke) and ALDH2 (stroke in East Asians). Research on personalized stroke risk prediction using polygenic risk scores is also actively under way.

Antiphospholipid syndrome is an acquired hypercoagulable state caused by autoantibodies (lupus anticoagulant, anticardiolipin antibodies, anti-beta-2 glycoprotein I antibodies) against APOH (beta-2 glycoprotein I) or other autoantigens, and is strongly associated with recurrent cerebral infarction at a young age. Inherited hypercholesterolemia (familial hypercholesterolemia due to LDLR, APOB and PCSK9 variants) also markedly increases the risk of premature atherosclerosis and associated cerebral infarction.


4. General epidemiology

Cerebral infarction is the second most common cause of death worldwide and a major cause of long-term disability. The annual number of ischemic strokes worldwide is about 13.4 million (as of 2019), of which about 80–85% are ischemic (cerebral infarction) and 15–20% hemorrhagic (intracerebral hemorrhage and subarachnoid hemorrhage). The annual incidence of cerebral infarction in various countries is about 95–290 per 100,000 population, but precise statistics in East Asian countries differ from those in the West. Stroke contributes to about 5.5 million deaths annually, about 10% of all deaths worldwide.

According to Korean health insurance data, there are more than about 100,000 stroke hospitalizations annually, of which ischemic stroke (cerebral infarction) accounts for about 75–80%. The incidence of cerebral infarction in Korea has shown a declining trend on an age-standardized basis over the past 30 years, but the absolute number of cases is actually increasing because of the growing older population. The median age at onset is in the early 70s, and incidence rises sharply in those aged 75 and over. By sex, incidence is higher in men under 75, but over 75 the incidence in women tends to catch up with that of men. Socioeconomically, incidence and mortality of cerebral infarction are higher in lower-income groups, reflecting differences in hypertension treatment rates, lifestyle and access to medical care.

According to the INTERSTROKE study, which analyzed the population attributable risk of major risk factors, hypertension accounts for about 48% of global stroke risk, smoking 12%, abdominal obesity 19%, physical inactivity 29%, diabetes 11%, atrial fibrillation 10% and alcohol 6%, and these 10 risk factors explain more than 90% of total stroke risk. This suggests that the potential for prevention through lifestyle improvement and risk factor management is very large.


5. Pathophysiology

The core pathophysiology of cerebral infarction is reduced regional cerebral blood flow due to cerebral vessel occlusion and the resulting neuronal death. When regional cerebral blood flow falls from normal (about 50–60 mL/100g/min) to below about 20 mL/100g/min, neurotransmission ceases and clinical symptoms begin to appear, and below 10 mL/100g/min, cellular energy depletion begins irreversible neuronal injury. The region that suffers severe ischemia after vessel occlusion is called the ischemic core, and the surrounding region of moderate ischemia, where function can recover with reperfusion, is called the ischemic penumbra. The goal of thrombolysis and endovascular treatment is to salvage this penumbra.

At the cellular level, ischemia induces neuronal death through multistep injury mechanisms. When Na+/K+ ATPase function declines because of energy depletion (ATP deficiency), Na+ and Ca2+ flow excessively into the cell and cellular edema develops. Intracellular Ca2+ overload leads to calcineurin activation, caspase activation, oxidative stress through NOS (nitric oxide synthase) overactivity, and mitochondrial dysfunction. Excitotoxicity due to excessive release of excitatory amino acids (glutamate) accelerates cell death by increasing Ca2+ influx through NMDA and AMPA receptors. In the penumbra, apoptosis acts as the main mechanism of death, so that more brain tissue becomes irreversibly damaged as time passes.

Secondary injury can occur even after reperfusion. Post-ischemic reperfusion injury includes explosive generation of reactive oxygen species (ROS), inflammatory cell infiltration, blood-brain barrier disruption and worsening cerebral edema. In hemispheric infarction, malignant cerebral edema develops 24–96 hours after ischemia and can sharply raise intracranial pressure and cause brain herniation, which is particularly fatal in young patients with complete middle cerebral artery occlusion. By mechanism of vessel occlusion, it is divided into thrombotic occlusion (thrombus formation after atherosclerotic plaque rupture), embolic occlusion (migration of emboli from the heart or proximal vessels) and hemodynamic ischemia (hypoperfusion, hemodynamic infarction), each differing in clinical course and treatment strategy.


6. Symptoms

The symptoms of cerebral infarction are determined by the territory supplied by the occluded vessel, and sudden onset is the most important clinical feature. Internationally, the FAST (Face drooping, Arm weakness, Speech difficulty, Time to call) criteria are used for recognizing stroke symptoms. The most common symptom is hemiplegia or hemiparesis, often involving the upper and lower limbs simultaneously. Lesions of the posterior limb of the internal capsule produce pure motor hemiplegia.

Speech disturbance appears with left (dominant) hemisphere lesions, and there are various types, including expressive aphasia (Broca), receptive aphasia (Wernicke), conduction aphasia and global aphasia. Dysarthria, in which language is fluent but pronunciation is unclear, commonly appears with basal ganglia, cerebellar and brainstem infarction. Visual disturbances may include homonymous hemianopia (occipital lobe lesions) or amaurosis fugax (transient monocular blindness, a warning sign of internal carotid infarction). Dizziness, nausea, vomiting and gait ataxia are characteristic symptoms of cerebellar or brainstem infarction. Wallenberg syndrome results from occlusion of the posterior inferior cerebellar artery (PICA) and is characterized by dysphagia, ipsilateral loss of facial pain sensation, contralateral loss of body pain sensation, ipsilateral Horner syndrome and nystagmus.

A transient ischemic attack (TIA) preceding symptom onset is a temporary neurological deficit that resolves completely within 24 hours and is an important warning sign of cerebral infarction. Because the risk of cerebral infarction within 48 hours to 90 days after a TIA is high, at about 10–15%, immediate evaluation and treatment are needed. The ABCD2 score (age, blood pressure, clinical features, symptom duration, diabetes) can estimate the short-term risk of cerebral infarction after TIA.


7. Signs

Neurological examination findings in cerebral infarction form specific syndromes according to infarct location and extent. Upper motor neuron signs include the Babinski reflex (dorsiflexion of the big toe on plantar stimulation), hyperactive deep tendon reflexes and spastic paralysis. However, in the acute phase, hypotonia and hyporeflexia may appear because of initial cerebral shock, so care must be taken to avoid confusion.

In middle cerebral artery (MCA) territory infarction, contralateral hemiplegia of the face, arm and leg (arm > leg), hemisensory loss, ipsilateral conjugate gaze deviation (gaze deviation toward the lesion) and contralateral hemianopia appear, accompanied by aphasia when the dominant hemisphere is involved and hemi-neglect when the nondominant hemisphere is involved. Anterior cerebral artery (ACA) territory infarction is characterized by hemiplegia with leg > arm, urinary incontinence, grasp reflex and frontal lobe symptoms (akinetic mutism, personality change). In posterior cerebral artery (PCA) territory infarction, contralateral hemianopia (loss of half the visual field), sensory abnormalities and memory impairment appear.

Brainstem infarction is characterized by crossed syndromes, with ipsilateral cranial nerve palsy and contralateral limb motor and sensory deficits. Weber syndrome (ipsilateral third nerve palsy + contralateral hemiplegia), Millard-Gubler syndrome (ipsilateral sixth and seventh nerve palsy + contralateral hemiplegia) and Wallenberg syndrome are textbook examples. Lacunar infarction is a small infarct due to small vessel occlusion and is characterized by four classic syndromes: pure motor hemiplegia, pure sensory stroke, ataxic hemiparesis and dysarthria–clumsy hand syndrome.


8. Screening

General population screening for cerebral infarction focuses on early detection of risk factors. Regular blood pressure measurement in all adults, with immediate treatment when hypertension is found, is the most important screening strategy for stroke prevention. Early detection of diabetes and prediabetes through blood glucose testing, screening for dyslipidemia through a fasting lipid profile, and screening for atrial fibrillation through electrocardiography (ECG) are recommended in high-risk groups. When pulse irregularity is suspected, 24–72-hour Holter ECG or long-term ECG monitoring (up to 30 days) is effective for detecting occult atrial fibrillation.

For asymptomatic carotid stenosis, screening with carotid ultrasound is considered in patients with an audible carotid bruit (cervical bruit) or other clinical evidence of atherosclerosis. However, general population screening for asymptomatic carotid stenosis is currently not recommended by most guidelines. In patients with a history of TIA or minor stroke, a comprehensive secondary prevention evaluation including cardiac monitoring, cerebrovascular imaging and blood tests (coagulation tests, autoantibodies, etc.), along with evaluation of the cause, is recommended to prevent recurrence. In high-risk inherited cerebrovascular diseases (family history of CADASIL, suspected Fabry disease), early detection through genetic testing and brain MRI is needed.

In patients with nonvalvular atrial fibrillation, assessing the risk of cerebral infarction with the CHA2DS2-VASc score and deciding to start anticoagulation are key to preventing cardioembolic cerebral infarction. Comprehensive vascular risk management through appropriate INR monitoring or monitoring of DOAC use, statin therapy and blood pressure control is essential in high-risk patients.


9. Diagnosis

Speed is key in diagnosing acute cerebral infarction. As soon as stroke symptoms appear, a non-contrast head CT is performed to first exclude cerebral hemorrhage. Early CT signs of hyperacute ischemic infarction include the hyperdense MCA sign (direct MCA density due to thrombus), loss of the sylvian fissure, loss of the gray-white matter boundary and sulcal effacement, but sensitivity is low, so MRI is performed when clinical suspicion is strong even if the CT is normal.

Diffusion-weighted MRI (DWI) is the standard for diagnosing acute ischemic cerebral infarction. DWI shows high-signal changes in the ischemic core within minutes of onset, allowing diagnosis of acute infarction with much higher sensitivity (over 95%) than CT. On the ADC (apparent diffusion coefficient) map, low ADC values (red) reflect the irreversible ischemic core. Perfusion MRI (perfusion-weighted imaging, PWI) or CT perfusion assesses the extent of the ischemic core and penumbra and is used to determine indications for reperfusion therapy.

Among vascular imaging tests, CT angiography (CTA) can most rapidly assess the site of vessel occlusion and collateral circulation in an emergency and is essential for planning mechanical thrombectomy. MR angiography (MRA) allows vascular assessment without radiation exposure, and digital subtraction angiography (DSA) is the definitive vascular imaging test, allowing precise assessment of vascular anatomy together with endovascular treatment. To evaluate the cause, ECG, 24-hour ECG monitoring, echocardiography (transthoracic and transesophageal) and blood tests (CBC, coagulation tests, blood glucose, cholesterol, autoantibodies, etc.) are performed.


10. Treatment

Time is key in reperfusion therapy for acute cerebral infarction ("Time is brain"). For intravenous thrombolysis, alteplase (0.9 mg/kg, maximum 90 mg, 10% as a bolus and the rest as a 60-minute infusion) is given within 4.5 hours of onset when cerebral hemorrhage has been excluded. Contraindications include stroke or serious head trauma within the past 3 months, intracranial or intraspinal surgery, blood pressure of 180/105 mmHg or higher, blood glucose below 50 mg/dL or above 400 mg/dL, active bleeding and recent anticoagulant use. Recently, tenecteplase (0.25 mg/kg) has attracted attention for showing effects similar to alteplase with the convenience of a single bolus injection.

Mechanical thrombectomy is performed for large vessel occlusion infarction due to occlusion of the internal carotid artery or the M1 segment of the middle cerebral artery within 6 hours of onset (without selection), or within 6–24 hours with patient selection by MRI or CT perfusion imaging (DAWN, DEFUSE-3 criteria). The thrombus is removed using a stent retriever or direct aspiration, and the recanalization rate (TICI 2b–3) exceeds 90%. When combined thrombolysis and endovascular treatment are possible, performing both concurrently is standard.

Acute-phase supportive care includes maintaining oxygen saturation, temperature control (immediate treatment of fever), glucose control (target 140–180 mg/dL), fluid therapy, and nutrition after swallowing assessment. For secondary prevention, antiplatelet agents (aspirin, clopidogrel or a combination) are used for non-cardioembolic infarction and anticoagulants (warfarin or DOAC) for cardioembolic (atrial fibrillation) infarction. Statins (high-intensity) are essential for preventing recurrence of atherosclerotic infarction. For symptomatic carotid stenosis (70% or more), carotid endarterectomy (CEA) or carotid artery stenting (CAS) is effective in preventing recurrent cerebral infarction.


11. Prognosis

The prognosis of cerebral infarction varies greatly with infarct extent, location, whether reperfusion occurs and the patient's baseline condition. Acute 30-day mortality is about 10–15%, and 1-year mortality about 20–30%. When early reperfusion is achieved with thrombolysis or mechanical thrombectomy, the rate of functional independence (mRS 0–2) at 3 months improves markedly. In the DAWN study, the 90-day functional independence rate in the mechanical thrombectomy group was 49%, far higher than the 13% in the medical treatment group. Because the effect of reperfusion decreases with time ("Time is brain"), the time to treatment is the key determinant of prognosis.

In the long-term prognosis of survivors, about 40–50% live with moderate to severe disability. Aphasia, cognitive decline, depression and post-stroke dementia are common long-term complications. Post-stroke depression occurs in about 30–40% of survivors and negatively affects rehabilitation adherence and functional recovery. The risk of recurrence is highest in the first year (about 10–12%), with recurrence of 4–5% each year thereafter. The greatest risk factors for early recurrence are atrial fibrillation, atherosclerotic carotid stenosis and cryptogenic infarction. Comprehensive secondary prevention including antiplatelet agents, anticoagulants, statins and antihypertensives can lower the risk of recurrence by up to about 80%. Intensive multidisciplinary rehabilitation (neurology, rehabilitation medicine, occupational therapy, speech therapy, physical therapy, psychotherapy) is essential to maximize functional recovery.

Indicators used for prognosis prediction include the initial NIHSS (National Institutes of Health Stroke Scale) score, infarct volume, success of reperfusion, collateral status, age and baseline functional status. An NIHSS of 5 or less is classified as mild stroke, 5–14 as moderate and 15 or more as severe, and the higher the initial NIHSS, the lower the likelihood of independent functional recovery. However, because functional recovery through post-stroke neuroplasticity proceeds over months to years, overly pessimistic early judgments about the possibility of recovery should be avoided.


12. Prevention

Primary prevention of cerebral infarction is preventing a first stroke by controlling risk factors. The single most important preventive measure is treatment of hypertension; keeping systolic blood pressure below 130 mmHg reduces stroke risk by about 35–45%. Smoking cessation lowers stroke risk more than 2-fold, and the risk falls to the level of nonsmokers 5–10 years after quitting. Diabetes control (target HbA1c below 7%) and treatment of dyslipidemia (LDL cholesterol below 70 mg/dL, below 55 mg/dL in high-risk groups) are essential for preventing atherosclerotic cerebral infarction.

For physical activity, at least 150 minutes per week of moderate aerobic exercise is recommended, and weight loss (BMI below 25) in obese patients has combined positive effects on blood pressure, blood glucose and lipids. A Mediterranean diet (centered on vegetables, fruit, fish and olive oil) is associated with reduced stroke risk. Avoiding heavy drinking (no more than 2 drinks a day for men and 1 for women) and avoiding illicit drugs (cocaine, amphetamines) are also important. When atrial fibrillation is diagnosed, starting anticoagulation at a CHA2DS2-VASc score of 2 or more (3 or more in women) is key to preventing cardioembolic cerebral infarction.

In secondary prevention (prevention of recurrence), treatment tailored to the cause is important. After non-cardioembolic ischemic stroke/TIA, combined aspirin + clopidogrel (short-term combination for the first 21 days, then monotherapy) lowers the risk of recurrence, followed by long-term maintenance with a single antiplatelet agent (aspirin or clopidogrel). After cardioembolic (atrial fibrillation) infarction, switching to warfarin or a DOAC is needed. In symptomatic carotid stenosis (70% or more), revascularization by CEA or CAS together with drug therapy is effective in preventing recurrence, and early performance within 14 days of symptom onset is recommended.


13. References

  1. Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke. Stroke. 2019;50(12):e344-e418. DOI: 10.1161/STR.0000000000000211. PMID: 31662037.

  2. Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med. 2018;378(1):11-21. DOI: 10.1056/NEJMoa1706442. PMID: 29129157.

  3. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317-1329. DOI: 10.1056/NEJMoa0804656. PMID: 18815396.

  4. Goyal M, Menon BK, van Zwam WH, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016;387(10029):1723-1731. DOI: 10.1016/S0140-6736(16)00163-X. PMID: 26898852.

  5. Johnston SC, Easton JD, Farrant M, et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med. 2018;379(3):215-225. DOI: 10.1056/NEJMoa1800410. PMID: 29766750.

  6. O'Donnell MJ, Xavier D, Liu L, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376(9735):112-123. DOI: 10.1016/S0140-6736(10)60834-3. PMID: 20561675.

  7. Kim BJ, Han MK, Park TH, et al. Current status of acute stroke management in Korea: a report on a multicenter, comprehensive stroke registry. Int J Stroke. 2014;9(4):514-518. DOI: 10.1111/ijs.12123. PMID: 23879752.

  8. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. TOAST. Stroke. 1993;24(1):35-41. DOI: 10.1161/01.STR.24.1.35. PMID: 7678184.

  9. Emberson J, Lees KR, Lyden P, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014;384(9958):1929-1935. DOI: 10.1016/S0140-6736(14)60584-5. PMID: 25106063.

  10. Feigin VL, Krishnamurthi RV, Parmar P, et al. Update on the global burden of ischemic and hemorrhagic stroke in 1990-2013: The GBD 2013 Study. Neuroepidemiology. 2015;45(3):161-176. DOI: 10.1159/000441085. PMID: 26505981.